Similar articles

• Beraprost therapy for pulmonary arterial hypertension.

  Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R; Beraprost Study Group. Barst RJ, et al. J Am Coll Cardiol. 2003 Jun 18;41(12):2119-25. doi: 10.1016/s0735-1097(03)00463-7. J Am Coll Cardiol. 2003. PMID: 12821234 Clinical Trial.
• Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension.

  Ikeda D, Tsujino I, Sakaue S, Ohira H, Itoh N, Kamigaki M, Ishimaru S, Atsumi T, Nishimura M. Ikeda D, et al. Circ J. 2007 Nov;71(11):1829-31. doi: 10.1253/circj.71.1829. Circ J. 2007. PMID: 17965512 Clinical Trial.
• Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.

  Galiè N, Humbert M, Vachiéry JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simonneau G; Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Galiè N, et al. J Am Coll Cardiol. 2002 May 1;39(9):1496-502. doi: 10.1016/s0735-1097(02)01786-2. J Am Coll Cardiol. 2002. PMID: 11985913 Clinical Trial.
• A new epoprostenol formulation for the treatment of pulmonary arterial hypertension.

  Fuentes A, Coralic A, Dawson KL. Fuentes A, et al. Am J Health Syst Pharm. 2012 Aug 15;69(16):1389-93. doi: 10.2146/ajhp110687. Am J Health Syst Pharm. 2012. PMID: 22855104 Review.
• [Therapy of severe pulmonary hypertension with prostacyclin and iloprost].

  Matthes J, Mathen F, Herzig S, Wassermann K. Matthes J, et al. Dtsch Med Wochenschr. 2001 May 25;126(21):631-7. doi: 10.1055/s-2001-14422. Dtsch Med Wochenschr. 2001. PMID: 11413752 Review. German. No abstract available.